Εμφάνιση απλής εγγραφής

dc.creatorScarmeas, N.en
dc.creatorBrandt, J.en
dc.creatorAlbert, M.en
dc.creatorHadjigeorgiou, G.en
dc.creatorPapadimitriou, A.en
dc.creatorDubois, B.en
dc.creatorSarazin, M.en
dc.creatorDevanand, D.en
dc.creatorHonig, L.en
dc.creatorMarder, K.en
dc.creatorBell, K.en
dc.creatorWegesin, D.en
dc.creatorBlacker, D.en
dc.creatorStern, Y.en
dc.date.accessioned2015-11-23T10:47:06Z
dc.date.available2015-11-23T10:47:06Z
dc.date.issued2005
dc.identifier10.1001/archneur.62.10.1601
dc.identifier.issn0003-9942
dc.identifier.urihttp://hdl.handle.net/11615/32928
dc.description.abstractBackground: Delusions and hallucinations are common in Alzheimer disease (AD) and there are conflicting reports regarding their ability to predict cognitive decline, functional decline, and institutionalization. According to all previous literature, they are not associated with mortality. Objective: To examine whether the presence of delusions or hallucinations has predictive value for important outcomes in AD. Design, Setting, and Participants: A total of 456 patients with AD at early stages (mean Folstein Mini-Mental State Examination [MMSE] score of 21 of 30 at entry) were recruited and followed up semiannually for up to 14 years (mean, 4.5 years) in 5 university-based AD centers in the United States and Europe. Using the Columbia University Scale for Psychopathology in AD (administered every 6 months, for a total of 3266 visit-assessments, average of 7.2 per patient), the presence of delusions and hallucinations was extracted and examined as time-dependent predictors in Cox models. The models controlled for cohort effect, recruitment center, informant status, sex, age, education, a comorbidity index, baseline cognitive and baseline functional performance, behavioral symptoms, and use of neuroleptics and cholinesterase inhibitors. Main Outcome Measures: Cognitive (Columbia MMSE score of <= 20/57 [approximate Folstein MMSE score of <= 10/30]), functional (Blessed Dementia Rating Scale [parts I and III score of 2 10), institutionalization equivalent index, and death. Results: During the full course of follow-up, 38% of patients reached the cognitive, 41% the functional, 54% the institutionalization, and 49% the mortality end point. Delusions were noted for 34% of patients at baseline and 70% at any evaluation. Their presence was associated with increased risk for cognitive (risk ratio [RR], 1.50; 95% confidence interval [CI], 1.07-2.08) and functional decline (RR, 1.41; 95% CI, 1.02-1.94). Hallucinations were present in 7% of patients at initial visit and in 33% at any visit. Their presence was associated with increased risk for cognitive decline (RR, 1.62; 95% CI, 1.06-2.47), functional decline (RR, 2.25; 95% Cl, 1.54-2.27), institutionalization (RR, 1.60; 95% CI, 1.13-2.28), and death (RR, 1.49; 95% Cl, 1.03-2.14). Conclusions: Delusions and hallucinations are very common in AD and predict cognitive and functional decline. Presence of hallucinations is also associated with institutionalization and mortality.en
dc.sourceArchives of Neurologyen
dc.source.uri<Go to ISI>://WOS:000232502900016
dc.subjectLEWY-BODY VARIANTen
dc.subjectPSYCHIATRIC-SYMPTOMSen
dc.subjectEXTRAPYRAMIDAL SIGNSen
dc.subjectCOGNITIVEen
dc.subjectDECLINEen
dc.subjectPSYCHOPATHOLOGICAL FEATURESen
dc.subjectPSYCHOLOGICAL SYMPTOMSen
dc.subjectFUNCTIONALen
dc.subjectSENILE DEMENTIAen
dc.subjectPROBABLE ADen
dc.subjectPREDICTORSen
dc.subjectClinical Neurologyen
dc.titleDelusions and hallucinations are associated with worse outcome in Alzheimer diseaseen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής